Esperion Therapeutics Inc
NASDAQ:ESPR
Esperion Therapeutics Inc
Goodwill
Esperion Therapeutics Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Goodwill
$48.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Goodwill
$21.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Goodwill
$71.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Goodwill
$21.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Goodwill
$5.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
Esperion Therapeutics Inc
Glance View
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
